14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934
Filed by the Registrant [ X ]
Filed by a Party other than the Registrant [ ]
Check the appropriate box:
[ ] Preliminary Proxy Statement
[ ] Confidential, for Use of the Commission Only (as Permitted by
Rule 14a-6(e)(2))
[ ] Definitive Proxy Statement
[ X ] Definitive Additional Materials
[ ] Solicitation Material Pursuant to Rule 14a-11(c) or rule 14a-12
Hemispherx Biopharma, Inc.
________________________________________________
(Name of Registrant as Specified in its Charter)
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[x] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
Title of each class of securities to which transaction applies:
Aggregate number of securities to which transaction applies: Per unit
price or other underlying value of transaction computed pursuant to
Exchange Act Rule 0-11:
Proposed maximum aggregate value of transaction:
----------------------
5) Total fee paid:
-------------------
[ ] Fee paid previously with preliminary materials.
[ ] Check box if any part of the fee is offset as provided by Exchange
Act Rule 0-11(a)(2) and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
(2) Form, Schedule or Registration Statement No.:
---------------------
(3) Filing Party:
(4) Date Filed:
Dear Stockholders of Hemispherx Biopharma,
It is extremely important that you vote your shares for the annual stockholder
meeting. If you have already voted, thank you for your participation. If you
have not, I strongly urge you to vote your proxy as soon as possible.
The record date remains July 21, 2008. The purposes for which the meeting is
being held remain the same as those listed in our Notice of Annual Meeting of
August 1, 2008.
United States stockholders will receive an additional proxy mailing
electronically or in the mail.
The following information is for European stockholders of Hemispherx:
A significant number of stockholders are domiciled in Europe and less readily
accessible for notification purposes. European banks do not forward the proxy to
European stockholders, and will need to contact your bank directly.
The following banks will vote directly on behalf of the stockholder as
instructed:
KBC - Contact Nadine Merckx at +32 2 429 2549 or e mail
general.meetings@kbcsecurities.be ATTN: Nadine Merckx in the subject line.
Dexia - Contact K. Nelis at +32 2 222 11 11
Fortis: Contact Kellen Van Liefferinge at +32 (0)2 210 42 52 or Tarik Daggouz at
+32 22748384
All others banks will issue a legal proxy or a certificate certifying the number
of shares owned, which must be accompanied by a signed and dated proxy. The
following is contact information to request a legal proxy or certificate:
Keytrade: Mr. Condotta at +32 2 679 9119 or
email paolo.condotta@keytradebank.com
Procapital Belgium: Jo Cuyvers at +32 2.505.01.60 or
email jo.cuyvers@procapital.be
ING: Sonia De Block at +32 2 738 21 21 or e mail sonia.de-block@ing.be
Please send a copy of the certificate accompanied by a signed and dated proxy
card as soon as possible via fax or e mail to:
Fax: +001 212 929 0308
e-mail: proxy@mackenziepartners.com or dwil@willstar.net
If your bank is not listed above, please contact me and I will assist you in
obtaining information on how to vote your shares.
Best regards,
Dianne Will
Investor Relations for Hemispherx Biopharma, Inc.
Dianne Will
Investor Relations
phone: 518-398-6222
e-mail: dwill@willstar.net
This communication and any files transmitted with it contain information that is
confidential and may be privileged and exempt from disclosure under applicable
law. It is intended solely for the use of the individual or entity to which it
is addressed. If you are not the intended recipient, you are hereby notified
that any use, dissemination or copying of this communication is strictly
prohibited. If you have received this communication in error, please notify the
sender. Thank you for your cooperation.